Clinical Study | Office of Clinical Research

Allovir For Kidney Transplant Patients With Bk Virus

Posted Date: Mar 1, 2021

Investigator: Ervin Steve Woodle
Specialties:
Type of Study: Drug

This multicenter, randomized, double-blind, placebo-controlled, multiple dosing interval, 3-period study of the safety, tolerability and effectiveness of adoptively transferred Viralym-M multivirus-specific T cells in kidney transplant recipients with low titers of BK viremia. The primary objective is to assess the safety and tolerability of Viralym-M and to test the hypothesis that administration of Viralym-M to kidney transplant recipients with BK viremia will demonstrate superiority in suppressing BK viral load compared with placebo.

Criteria:

Kidney Transplant Recipient With Bk Virus In The Blood

Keywords:

Kidney Transplant, Bk Virus

For More Information:

Amanda Naciff Stahl
558-9965
naciffab@ucmail.uc.edu

Name*
First Last
Gender*
- Male
- Female
Age*
Phone*
Email*
How did you hear about us?*
Future Communication*
- By submitting this form, I am agreeing to receive future communication about participating in an upcoming research study.
CAPTCHA
This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.
List